Use access key #2 to skip to page content.
$30.90 -2.54 (-7.60%)
10/6/2008 4:07 PM

Sanofi-Aventis (ADR) (SNY)

CAPS Rating:
*****

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.

View All Commentary (SNY)

Recs

2

Avatar frankp102 (< 20) Submitted: 8/24/06 8:50 PM : Outperform Start Price: $41.79 SNY Score: -6.44

SNY has new drug (rimonabant) in a new class of drugs (endocannabinoid receptor antagonist) which is effective in weight loss, metabolic syndrome, raises HDL (good cholesterol) an helps quit smoking. This drug has been approved in Europe and UK this spring. Pending FDA approval late this fall.

Report this Post Replies: 0 | Reply

Featured Broker Partners